Psychiatry and Neurology, Neurology · Annandale, NJ
NPI
1457345324
Since 2005
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
4
Medicare group memberships
Hospitals
4
Hospital affiliations
1322 Route 31
Annandale, NJ, 08801
Phone (908) 894-7222
Groups this clinician bills Medicare through
Medicare paid, 2024
$6.8M
411,871 services
Medicare patients, 2024
756
Average age 73
Drug cost, 2024
$4.8M
6,598 prescriptions
Company payments, 2025
$9,381
From 39 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Manish B Viradia was code J0174 (injection, lecanemab-irmb, 1 mg), 165,300 times for 19 patients. In total Manish B Viradia billed 411,871 services in 72 codes, and Medicare paid $6.8M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-10-25.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0174 Injection, lecanemab-irmb, 1 mg | Office | 165,300 | 19 | $1.05 | $173K |
| J0585 Injection, onabotulinumtoxina, 1 unit | Office | 78,900 | 94 | $4.93 | $389K |
| J1568 Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 67,280 | 54 | $36.28 | $2.4M |
| J2350 Injection, ocrelizumab, 1 mg | Office | 17,400 | 18 | $45.27 | $788K |
| J3032 Injection, eptinezumab-jjmr, 1 mg | Office | 11,200 | 15 | $14.40 | $161K |
| J2919 Injection, methylprednisolone sodium succinate, 5 mg | Office | 2,550 | 33 | $0.23 | $578 |
| 96366 Intravenous Infusion, Hydration | Office | 1,125 | 61 | $15.97 | $18K |
| 99214 Office E&M - Established | Office | 897 | 537 | $92.11 | $83K |
| 96365 Intravenous Infusion, Hydration | Office | 848 | 81 | $50.33 | $43K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 568 | 393 | $12.25 | $6,959 |
| 96375 Injection Administration | Office | 461 | 65 | $11.97 | $5,518 |
| 99213 Office E&M - Established | Office | 423 | 195 | $68.07 | $29K |
| 96413 Chemotherapy Administration | Office | 328 | 64 | $104.74 | $34K |
| J1200 Injection, diphenhydramine hcl, up to 50 mg | Office | 306 | 60 | $0.60 | $183 |
| 99204 Office E&M - New | Office | 154 | 154 | $116.19 | $18K |
By year: 2022 $4.4M for 176,087 services; 2023 $4.9M for 218,173 services; 2024 $6.8M for 411,871 services.
Medicare prescription drug claims, 2024
In 2024, the drug Manish B Viradia prescribed most often to Medicare patients was Gabapentin, with 611 prescriptions and refills. In total Manish B Viradia wrote 6,598 Medicare prescriptions that cost $4.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Gabapentin Generic | 611 | 1,380 | 176 | $16K |
| Pregabalin Generic | 324 | 440 | 63 | $4,540 |
| Alprazolam Generic | 297 | 355 | 67 | $1,812 |
| Diazepam Generic | 249 | 317 | 47 | $2,156 |
| Memantine Hcl Generic | 244 | 585 | 71 | $7,032 |
| Butalbital-Acetaminophen-Caffe Butalb/Acetaminophen/Caffeine | 196 | 196 | 34 | $3,847 |
| Primidone Generic | 183 | 442 | 44 | $6,580 |
| Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine | 172 | 172 | 33 | $5,020 |
| Carbidopa-Levodopa Carbidopa/Levodopa | 151 | 358 | 46 | $4,395 |
| Topiramate Generic | 143 | 289 | 34 | $3,005 |
| Baclofen Generic | 126 | 297 | 33 | $4,069 |
| Sumatriptan Succinate Generic | 109 | 133 | 18 | $1,044 |
| Clonazepam Generic | 107 | 135 | 21 | $1,416 |
| Rytary Carbidopa/Levodopa | 107 | 203 | 26 | $81K |
| Cyclobenzaprine Hcl Generic | 104 | 146 | 30 | $954 |
Brand drugs: 1,054 claims; generic drugs: 5,529 claims; opioid claims: 168.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Manish B Viradia $9,381 ($9,381 in general payments such as food, travel and fees) from 39 companies. The largest payer was Argenx US, Inc. with $6,391.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.